3.

Comparison of OS and PFS by prognostic group for patients treated with first-line afatinib in LUX-Lung 3 and 6

		OS			PFS
Prognostic group	Prognostic score	Median [95% CI] T2E (month)	36-month OS probability (%)		Median [95% CI] T2E (month)	24-month PFS probability (%)
CI, confidence interval; OS, overall survival; PFS, progression free survival; T2E, time to event
Favourable	7 or below	>47.7 [41.5->47.7]	61.2 [52.6–71.3]		17.3 [15-25.2]	40.2 [31.9-50.7]
Intermediate	8 to 13	29.3 [24.2-31.7]	35.6 [29.4-43.1]		13.2 [11-13.9]	18.5 [14-24.6]
Poor	14 or above	16.4 [14-19.6]	13.6 [8.3-22.4]		8.3 [6.7–10.8]	8.9 [5.1-15.6]